Epic Sciences Raises $30M in Private Financing; Lucier Named Chairman | GenomeWeb

NEW YORK (GenomeWeb) – Epic Sciences has raised $30 million in a Series C round of private financing that it will use to support development of its circulating tumor cell analysis platform.

The San Diego-based firm is developing a circulating rare cell analysis platform with a particular focus on developing products and services to detect CTCs in cancer. It plans to market molecular diagnostic tests that rapidly quantify proteomic and genomic changes that occur over time during the treatment of a patient's cancer from a minimally invasive liquid biopsy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.